Document is current
Any future updates will be listed below
-
Authors
Italiano, A. https://orcid.org/0000-0002-8540-5351
Bessede, A.
Pulido, M.
Bompas, E. https://orcid.org/0000-0003-4414-7760
Piperno-Neumann, S.
Chevreau, C.
Penel, N.
Bertucci, F.
Toulmonde, M.
Bellera, C.
Guegan, J. P.
Rey, C.
Sautès-Fridman, C. https://orcid.org/0000-0003-1735-8722
Bougoüin, A.
Cantarel, C.
Kind, M.
Spalato, M.
Dadone-Montaudie, B.
Le Loarer, F. https://orcid.org/0000-0001-8582-9819
Blay, J. Y. https://orcid.org/0000-0001-7190-120X
Fridman, W. H. https://orcid.org/0000-0002-1332-0973
-
Funding
Funding for this research was provided by:
MSD, INCA DGOS, ARC
- License Information
-
More Information
Article History
Received: 11 November 2021
Accepted: 8 April 2022
First Online: 26 May 2022
Competing interests
: A.Bessede, J.P.G. and C.R. are employees of Explicyte. A.I. received research grants from AstraZeneca, Bayer, BMS, Chugai, Merck, MSD, Pharmamar, Novartis and Roche and personal fees from Epizyme, Bayer, Deciphera, Lilly, Parthenon, Roche and Springworks. W.H.F. received a research grant from AstraZeneca and personal fees from Anaveon, AstraZeneca, Catalym, Elsalys, Novartis, OSE Immunotherapeutics and Parthenon. J.Y.B. received research grants from Bayer, GSK, Merck, Novartis, Pharmamar and Roche and personal fees from Bayer, GSK, Lilly, Novartis, Pharmamar and Roche. All other authors have no competing interests.
